Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Status of Circulating Tumor DNA and Its Impact on Adjuvant Chemotherapy Following Resection of Colorectal Liver Metastases

  • By

  • Kozo Kataoka

  • Kazuma Ito

  • Yoshiaki Nakamura

  • Jun Watanabe

  • Naoya Akazawa

  • Jun Nagata

  • Mitsuru Yokota

  • Kentaro Kato

  • Masahito Kotaka

  • Tadayoshi Hashimoto

  • Kentaro Yamazaki

  • Yoshinori Kagawa

  • Saori Mishima

  • Koji Ando

  • Masaaki Miyo

  • Hiroki Yukami

  • Arkarachai Fungtammasan

  • Shruti Sharma

  • J. Bryce Ortiz

  • Matthew Rabinowitz

  • Robert W. Lentz

  • Adham Jurdi

  • Minetta C. Liu

  • Alexey Aleshin

  • Daisuke Kotani

  • Hideaki Bando

  • Hiroya Taniguchi

  • Ichiro Takemasa

  • Takeshi Kato

  • Takayuki Yoshino

  • Eiji Oki

  • CIRCULATE-Japan Group

  • Kei Kimura

  • Ikuo Matsuda

  • Masataka Ikeda

  • Yuko Fukumoto

  • Satoshi Kobayashi

  • Hiroki Sokuoka

  • September 1, 2026

Share

Clinical Scorecard: Status of Circulating Tumor DNA and Its Impact on Adjuvant Chemotherapy Following Resection of Colorectal Liver Metastases

At a Glance

Category

Detail

Condition

Colorectal Liver Metastases (CRLM)

Key Mechanisms

Circulating tumor DNA (ctDNA) as a biomarker for molecular residual disease (MRD) and recurrence risk.

Target Population

Patients with colorectal cancer undergoing curative-intent hepatectomy for CRLM.

Care Setting

Oncology clinical practice and research settings.

Key Highlights

  • Recurrence affects up to two-thirds of patients post-hepatectomy for CRLM.

  • ctDNA positivity is linked to higher recurrence risk and poorer survival outcomes.

  • Adjuvant chemotherapy (ACT) may improve disease-free survival in MRD-positive patients.

  • Optimal patient selection for ACT remains unresolved.

  • The CIRCULATE-Japan GALAXY study evaluates ctDNA status in CRC patients.

Guideline-Based Recommendations

Diagnosis

  • Utilize ctDNA to assess molecular residual disease post-surgery.

Management

  • Consider ACT for patients with MRD positivity following CRLM resection.

Monitoring & Follow-up

  • Monitor ctDNA levels at multiple postoperative time points to assess recurrence risk.

Risks

  • Patients with MRD negativity may not benefit from ACT.

Patient & Prescribing Data

Patients with resected CRLM and available MRD status.

NAC cohort had more complex cases compared to the upfront surgery cohort.

Clinical Best Practices

  • Employ personalized tumor-informed multiplex PCR-based NGS assays for ctDNA detection.

  • Conduct longitudinal follow-up to monitor ctDNA and recurrence.

Related Resources & Content

  1. The ASCO Post, July 2026 -- ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases

  2. The ASCO Post, March 25, 2025 -- Advancing Clinical Decisions With Circulting Tumor DNA: Insights From Recent Clinical Trials

  3. The ASCO Post, January 2024 -- Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

  4. The ASCO Post, March 10, 2024 -- Studies Show Progress in Using ctDNA to Guide Colorectal Cancer Treatment

  5. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | JCO Oncology Practice

  6. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial - PMC

  7. Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases - PubMed

  8. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | JCO Oncology Practice

  9. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial - PMC

  10. Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases - PubMed

Original Source(s)

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases

  • by Kozo Kataoka, Kazuma Ito, Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa, Jun Nagata, Mitsuru Yokota, Kentaro Kato, Masahito Kotaka, Tadayoshi Hashimoto, Kentaro Yamazaki, Yoshinori Kagawa, Saori Mishima, Koji Ando, Masaaki Miyo, Hiroki Yukami, Arkarachai Fungtammasan, Shruti Sharma, J. Bryce Ortiz, Matthew Rabinowitz, Robert W. Lentz, Adham Jurdi, Minetta C. Liu, Alexey Aleshin, Daisuke Kotani, Hideaki Bando, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Takayuki Yoshino, Eiji Oki, CIRCULATE-Japan Group, Kei Kimura, Ikuo Matsuda, Masataka Ikeda, Yuko Fukumoto, Satoshi Kobayashi, Hiroki Sokuoka

  • September 1, 2026

Related Content

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min
AI-Designed Binder Improves CAR T Cell Activity in Mice

Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control

  • September 15, 2026

  • 3 min
Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling